Cluster 0: obstruction bowel signs symptoms starting drugs history month current study
Cluster 1: received prior patients treatment days therapy study chemotherapy dose previously
Cluster 2: study pregnant contraception agree participation adequate duration men women use
Cluster 3: patients prior study eligible disease patient history treatment days registration
Cluster 4: consent informed signed sign dated form written patient institutional guidelines
Cluster 5: platelets microliters plt dependent study day transfusion dose weeks treatment
Cluster 6: composition compounds similar attributed chemical allergic reactions biologic used agents
Cluster 7: karnofsky eastern cooperative ecog performance group oncology status kps greater
Cluster 8: neutrophil absolute count mm microliters cells randomization enrollment weeks days
Cluster 9: transfusion hemoglobin dl days blood past enrollment prior administration preceding
Cluster 10: platelet count mm days registration randomization prior mcl obtained ml
Cluster 11: limits normal institutional creatinine upper bilirubin days uln registration serum
Cluster 12: iuln bilirubin total upper registration institutional limit normal days prior
Cluster 13: mother breastfeeding discontinued treated pregnant excluded women study vx mln
Cluster 14: transaminase aminotransferase uln serum ast glutamic alt liver sgot sgpt
Cluster 15: absolute neutrophil mcl count growth hematopoietic factors days prior ul
Cluster 16: illness uncontrolled compliance social situations psychiatric intercurrent pectoris requirements arrhythmia
Cluster 17: expectancy life greater months weeks appropriate patient estimated sequencing equal
Cluster 18: solid marrow tumors bone involvement known peripheral count anc patients
Cluster 19: informed federal nature accordance guidelines sign written consent investigational institutional
Cluster 20: hcv hepatitis hbv virus infection cleared known chronic patients eligible
Cluster 21: requiring hypothyroidism autoimmune mellitus recur trigger psoriasis diabetes expected vitiligo
Cluster 22: state curative survival quality therapy prolong current proven life acceptable
Cluster 23: hemoglobin dl transfused level weeks unsupported hg mg randomization criterion
Cluster 24: cancer adequately treated surveillance cell program patient localized followed cervical
Cluster 25: aminotransferase alt ast alanine aspartate uln iuln institutional days registration
Cluster 26: corticosteroids steroids systemic prednisone mg inhaled immunosuppressive topical daily doses
Cluster 27: transaminase aminotransferase serum sgpt glutamic sgot glutamate pyruvate oxaloacetic alt
Cluster 28: complications resolved related infectious medical significant induction consolidation therapy cycle
Cluster 29: brain metastases treated patients stable prior treatment mri imaging untreated
Cluster 30: investigational receiving agents patients ineligible participants study treatment trials cancer
Cluster 31: score lansky years karnofsky performance age patients status paralysis ambulatory
Cluster 32: contraceptive measures reproductive pregnancy effective bilateral potential use time celibacy
Cluster 33: creatinine clearance gault min formula cockcroft ml calculated hour serum
Cluster 34: acquisition muga ejection fraction echocardiogram left gated ventricular multi scan
Cluster 35: sequencing antiretroviral combination immunodeficiency ineligible hiv biopsy virus human positive
Cluster 36: understand document willingness ability written sign informed consent able guardian
Cluster 37: zubrod performance status patients registration days prior criteria step study
Cluster 38: creatinine clearance min ml calculated serum measured uln crcl obtained
Cluster 39: leukocytes mcl mm ul lower registration equal days initiation obtained
Cluster 40: bilirubin upper normal limit total uln institutional times days prior
Cluster 41: swallow able pills absorb medication patients inability drug explained experiencing
Cluster 42: karnofsky performance status days step registration prior score sequencing ecog
Cluster 43: guardians legal parents sign written informed consent patients assent according
Cluster 44: mg years age dl males creatinine females serum maximum min
Cluster 45: higher neuropathy grade peripheral terminology common ctcae events adverse step
Cluster 46: capsules swallow able patients tube nasogastric broken crushed inability tablets
Cluster 47: major procedure surgical anticipation traumatic injury course days biopsy need
Cluster 48: vessels invading encasing major blood tumor subject contact indicate participant
Cluster 49: fda food nci institute met national studies requirements human administration
Cluster 50: immunodeficiency hiv virus human known positive infection patients excluded individuals
Cluster 51: childbearing pregnancy test potential negative women serum registration days prior
Cluster 52: creatinine institutional normal levels clearance min ml upper limit patients
Cluster 53: bp mmhg pressure blood antihypertensive diastolic systolic hypertension medications controlled
Cluster 54: platelets mm prior weeks days equivalent cell randomization ctcae enrollment
Cluster 55: representatives assent parents legally authorized according appropriate guidelines sign written
Cluster 56: platelets mcl platelet transfusion transfusions requiring plt weeks equal cells
Cluster 57: institutions identity process ensure board approval order open date entered
Cluster 58: weeks entering recovered adverse events earlier administered nitrosoureas mitomycin agents
Cluster 59: interstitial lung pneumonitis disease history pulmonary patients detection known symptomatic
Cluster 60: aminotransferase aspartate ast alanine upper alt normal limit uln institutional
Cluster 61: consecutive female childbearing months mature naturally potential postmenopausal menses bilateral
Cluster 62: conjugated sum unconjugated age bilirubin uln upper limit normal subprotocols
Cluster 63: monitoring comply safety opinion investigator able requirements eligible study patients
Cluster 64: corticosteroids decreasing stable corticosteroid dose receiving days prior mri patients
Cluster 65: platelet independent transfusion transfusions mm count enrollment defined receiving involvement
Cluster 66: oximetry pulse dyspnea rest air room exercise evidence intolerance breathing
Cluster 67: limits bilirubin normal total institutional uln upper gilberts direct registration
Cluster 68: transplantation organ solid received allogeneic prior eligible patients marrow bone
Cluster 69: nodal lesions mm measured measurable axis short longest recorded accurately
Cluster 70: sgpt alt uln purpose alanine transaminase glutamate pyruvate aminotransferase serum
Cluster 71: step registration prior weeks mcl induction screening treatment optional pre
Cluster 72: gog performance gynecologic status group oncology patients grade patient protocol
Cluster 73: bearing pregnancy test child negative females potential urine serum prior
Cluster 74: female pregnancy childbearing potential pregnant test negative patients result urine
Cluster 75: study agree contraception use male pregnant potential dose effective method
Cluster 76: phase study weeks administered levels referred eligibility early recovered prior
Cluster 77: fraction echocardiogram shortening ejection radionuclide angiogram gated cardiac echo study
Cluster 78: hepatitis antibody positive antigen hcv surface virus negative hbsag core
Cluster 79: time measurements obtain prothrombin ptt thromboplastin pt normalized inr neurologic
Cluster 80: chemotherapy randomization surgery adjuvant administered days breast neoadjuvant cancer interval
Cluster 81: marrow bone peripheral blood blasts biopsy aspirate patients performed involvement
Cluster 82: metastatic disease locally advanced patients evidence unresectable prior cancer definitive
Cluster 83: uncontrolled infection eligible patients active patient step subprotocols excluded general
Cluster 84: nursing childbearing pregnancy test pregnant negative women potential required registration
Cluster 85: granulocytes ul anc cells mcl absolute extending explained experiencing experimental
Cluster 86: eiaed epileptic drugs inducing anti enzyme taking patients previously enrolled
Cluster 87: forms medically willing sexually acceptable able contraception childbearing women men
Cluster 88: investigational currently drug receiving eligible patients anticancer therapy ineligible anti
Cluster 89: medications systemic adrenocortical anti tnf mineralocorticoids azathioprine orthostatic fludrocortisone dose
Cluster 90: months teaspoon dose hemoptysis red treatment study indicative bleeding hemorrhage
Cluster 91: ul platelet count transfusion cells independent cd unsupported platelets days
Cluster 92: ischemic revascularization artery event procedures including fibrillation ventricular cerebrovascular attack
Cluster 93: thromboplastin partial time aptt ptt activated uln normal upper limit
Cluster 94: hodgkin expansion lymphoma cohort participants enrollment weeks prior dl serum
Cluster 95: pd anti prior therapy treatment agents patients ctla antibody progression
Cluster 96: consent mandatory provide specific study entry informed tissue submission including
Cluster 97: monoclonal hypersensitivity antibody reaction severe history ineligible grade exclusion stratum
Cluster 98: physical examination history registration days complete prior prestudy obtained patients
Cluster 99: myelodysplastic mds aml leukemia myeloid syndrome acute suggestive features smear
Cluster 100: albumin dl serum days registration patients prior hypersensitivity mg inclusion
Cluster 101: syndrome fanconi anemia bloom telangiectasia shwachman kostmann ataxia known genetic
Cluster 102: protein urine urinalysis hour mg dipstick proteinuria screened obtained electrophoresis
Cluster 103: qtc prolong drugs alternatives interval receiving pointes torsades cause alternative
Cluster 104: bisphosphonate hypercalcemia osteoporosis reasons taking therapy use metastasis symptomatic allowed
Cluster 105: triglyceride mg dl level fasting serum applicable mmol gsk nf
Cluster 106: peripheral anc neutrophil absolute mm count zubrod exposed experimental expert
Cluster 107: dmso immediate chemically dimethyl sulfoxide excipients idiosyncrasy delayed trametinib hypersensitivity
Cluster 108: left fraction ejection ventricular lvef normal institutional function indicated heart
Cluster 109: aallb aall apecb open enrolled enrollment patients classification project sample
Cluster 110: expectancy life weeks patients estimated participants physician years procurement year
Cluster 111: creatinine uln serum institutional times obtained grade prior days randomization
Cluster 112: performance ecog status ps patients step registration score criteria greater
Cluster 113: accepted males abstain sexually intercourse effective advised sexual contraception strongly
Cluster 114: phosphatase alkaline uln involvement iuln days liver prior registration bone
Cluster 115: cancer breast invasive situ skin years malignancy carcinoma non melanoma
Cluster 116: inhibitor parp mek prior treatment kinase braf patients received therapy
Cluster 117: help occasional care karnofsky able performance status patient patients kps
Cluster 118: abdominal abscess intra perforation gastrointestinal fistula months obstruction history diverticulitis
Cluster 119: permitting authorization release personal information health signed approved informed consent
Cluster 120: qt qtc interval milliseconds corrected torsades pointes prolongation long congenital
Cluster 121: pre criteria registration eligibility inclusion step experiences experiencing experimental expert
Cluster 122: humanized anaphylactic proteins chimeric antibodies fusion allergic reactions severe hypersensitivity
Cluster 123: cardiac heart york association iii resulting activity iv new physical
Cluster 124: corticosteroids brain anticonvulsants inducing enzyme subjects weeks stable metastases month
Cluster 125: inr normalized international ratio time thromboplastin prothrombin ptt partial uln
Cluster 126: transfusions hematologic evaluable toxicity provided red known platelet meet refractory
Cluster 127: half lives whichever dose shorter days investigational minimum preceding study
Cluster 128: major surgery days registration prior delayed immunotherapy toxicity treatment extensive
Cluster 129: heart myocardial infarction failure months congestive angina history york association
Cluster 130: creatinine mg dl serum registration iuln days prior umol level
Cluster 131: glucose fasting mg dl blood diabetes serum mellitus age random
Cluster 132: chinese hamster ovary recombinant products hypersensitivity antibodies cell human known
Cluster 133: transplant stem cell allogeneic autologous prior graft host patients transplantation
Cluster 134: compounds composition chemical similar attributed allergic reactions biologic history mln
Cluster 135: fistula gastrointestinal perforation history abdominal months repaired postoperative starting surgically
Cluster 136: tacrolimus cyclosporine transplant prevent host post versus graft marrow trial
Cluster 137: anthracycline intravesical therapy prior excluded systemic patients muscle previous urothelial
Cluster 138: pregnant breastfeeding women excluded study discontinued treatment drug dose refrain
Cluster 139: provide informed consent written able willing ability inability patients unable
Cluster 140: calc creatinine calculated min clearance ml uln upper mg normal
Cluster 141: chemotherapy cancer different allowable prior systemic note study egf current
Cluster 142: weeks prior therapy study completed radiation shorter recovered half toxicity
Cluster 143: platelets mcl registration days prior obtained equal administration start step
Cluster 144: gp inhibitors glycoprotein inducers bcrp strong binding member cypa adenosine
Cluster 145: females method agreed males contraceptive reproductive effective participate unless menarchal
Cluster 146: absolute neutrophil count ul anc peripheral unsupported cells lymphocyte weeks
Cluster 147: oral swallow medications ability medication retain able absorption gastrointestinal unable
Cluster 148: rvo retinal occlusion vein history evidence current risk csr intraocular
Cluster 149: dependency tpn hydration nutrition parenteral iv total intravenous current participants
Cluster 150: anc neutrophil absolute count mcl registration days prior obtained equal
Cluster 151: hemoglobin dl hgb achieve intervention transfusion acceptable note use days
Cluster 152: overlap fields radiation result pelvis therapy neck head irradiation previous
Cluster 153: investigational agent receiving received treatment days neoplasm type patients dose
Cluster 154: nursing pregnant women mothers patients excluded unwilling pregnancy step birth
Cluster 155: anticonvulsants seizure inducing enzyme disorder controlled enrolled seizures patients non
Cluster 156: area surface body bsa enrollment patients time study mg level
Cluster 157: adverse events common terminology ctcae grade criteria version alopecia prior
Cluster 158: antiretroviral combination hiv ineligible immunodeficiency positive human virus therapy patients
Cluster 159: recist measurable response criteria solid evaluation disease tumors evaluable defined
Cluster 160: alchemist screen alliance registered trial randomization prior patients express expressing
Cluster 161: histologically confirmed cytologically cancer diagnosis metastatic patients proven unresectable cell
Cluster 162: age years score walk wheelchair ambulatory assessing performance lansky patients
Cluster 163: carcinoma cell squamous skin basal situ malignancies treated malignancy years
Cluster 164: specific informed consent provide study registration signed representative prior legally
Cluster 165: protein urine ratio upc creatinine upcr proteinuria hour dipstick collection
Cluster 166: mg dl years male female age creatinine gender radioisotope gfr
Cluster 167: stage iv iii disease patients cancer ii carcinoma ovarian diagnosis
Cluster 168: transfusions hemoglobin rbc dl red receive blood cell requiring involvement
Cluster 169: history coronary heart evidence cardiac controlled mmhg current defined subjects
Cluster 170: sensory motor neuropathy grade ctcae peripheral terminology common equal events
Cluster 171: blocks slides tissue notified unavailable sent chair enrollment available study
Cluster 172: myelosuppressive days dose enrollment prior chemotherapy agent immunomodulatory elapsed nitrosourea
Cluster 173: step randomization ii prior days dl bilirubin mg cells mm
Cluster 174: hiv licensed assay record approved documentation test rapid western blot
Cluster 175: return enrolling institution follow willing alliance willingness monitoring active phase
Cluster 176: radiation therapy prior chemotherapy received weeks patients pelvic elapsed treatment
Cluster 177: eligibility criteria step randomization registration induction meet preregistration screening operative
Cluster 178: radiotherapy weeks prior chemotherapy patients therapy entering study mitomycin nitrosoureas
Cluster 179: edition ajcc committee joint th american cancer stage staging nsclc
Cluster 180: white wbc blood ul count cell cells randomization prior obtained
Cluster 181: days events adverse infusion growth known agent elapsed occurring extended
Cluster 182: rankl denosumab atezolizumab discontinue treatment inhibitor requiring patients kappa require
Cluster 183: hsp inhibitor prior therapy received treatment patients zubrod expiratory experiences
Cluster 184: immunocompromised hiv positive immunodeficiency virus human known corticosteroids related patients
Cluster 185: laboratory clia certified mutation braf improvement clinical amendments approved mutations
Cluster 186: years age lansky performance ecog karnofsky scores cooperative eastern corresponding
Cluster 187: qt syndrome long congenital qtc family history ecg corrected msec
Cluster 188: standard survival prolong therapy progressed histologically tumors solid shown exist
Cluster 189: anc neutrophil absolute mm count cells days registration prior obtained
Cluster 190: pregnant partner participating inform suspect immediately woman physician treating study
Cluster 191: cns nervous central metastases involvement patients disease brain lumbar puncture
Cluster 192: cytochrome subfamily cypa family polypeptide strong inhibitors inducers cypc medications
Cluster 193: brain metastases carcinomatous meningitis remained stable trial patients clinical metastatic
Cluster 194: reproductive contraceptive sexually effective method agreed duration potential use participation
Cluster 195: infection exhibiting bacterial fungal signs despite improvement antibiotics symptoms appropriate
Cluster 196: cancer adequately treated cell basal patient squamous free situ skin
Cluster 197: corticosteroid dose modify corticosteroids days elapsed immune decreasing stable related
Cluster 198: signs symptoms cycle infection day weeks prior tuberculosis clinical active
Cluster 199: choice apecsc actionable match assignment given molecular analysis mutation presence
Cluster 200: lln calcium serum magnesium potassium lower phosphorus limit normal delaying
Cluster 201: feeding breast women pregnant females eligible lactating study girls menarchal
Cluster 202: permit circumstances follow completion required study travel issue instance patients
Cluster 203: fathering willing childbearing birth control child potential medically form treated
Cluster 204: hiv retroviral positive opportunistic virus haart immunodeficiency human cd regimen
Cluster 205: therapy prior chemotherapy cancer systemic patients hormonal treatment anti radiation
Cluster 206: retain stomach malabsorption bowels alter medication abnormalities swallow absorption major
Cluster 207: pressure blood mmhg hypertension systolic diastolic hypertensive uncontrolled controlled hg
Cluster 208: egfr exon tki tm mutation generation erlotinib deletion treatment testing
Cluster 209: lln echo lower left echocardiogram ejection ventricular fraction institutional limit
Cluster 210: male female years creatinine age gender follows serum based radioisotope
Cluster 211: pt anticoagulant ptt time thromboplastin anticoagulants intended therapeutic range partial
Cluster 212: ast uln alt performed aminotransferase instead registration value lab practice
Cluster 213: endotracheal endobronchial tumor evidence invading tract gi esophagus anus rectum
Cluster 214: syndrome patients gilberts known excluded trisomy necrolysis stevens history epidermal
Cluster 215: cholesterol mg dl level serum fasting mmol total draw gsk
Cluster 216: investigational agents weeks receive past received planning patients receiving anticancer
Cluster 217: wound healing fracture ulcer non bone cabozantinib dose surgeries history
Cluster 218: transaminase serum aminotransferase sgot glutamic oxaloacetic ast uln aspartate sgpt
Cluster 219: maximum creatinine mg dl male age serum female years gender
Cluster 220: hemoglobin dl days registration prior randomization obtained step transfusions weeks
Cluster 221: strong cypc miscellaneous inducers cypa inhibitors wort st antibiotics agents
Cluster 222: age bilirubin total upper uln limit normal direct times institution
Cluster 223: bilirubin uln total gilbert serum known level upper normal enrolled
Cluster 224: significant unrelated organ dysfunction infections hepatic results interfere systemic procedures
Cluster 225: phase ii arms randomized portion patients criteria registration weeks prior
Cluster 226: brain metastases trial excluded clinical known patients participants described trials
Cluster 227: hepatitis known infection active virus chronic hiv viral patients immunodeficiency
Cluster 228: gfr glomerular filtration rate min ml creatinine radioisotope clearance estimated
Cluster 229: measurable disease ct recist patients imaging tomography mri assessed resonance
Cluster 230: tumors verification patients original elevations relapse fetoprotein beta hcg intrinsic
Cluster 231: bilirubin gilberts uln total normal upper syndrome limit institutional unless
Cluster 232: ul platelets mcl untransfused unsupported cells sequencing biopsy treatment tumor
Cluster 233: cypa inducers strong inhibitors medications drugs use substances concomitant moderate
Cluster 234: ctcae grade alopecia nci version institute terminology national unresolved common
Cluster 235: fasting triglycerides mg dl equal cholesterol mmol lowering lipid values
Cluster 236: years age enrollment patients time performance scale months lansky study
Cluster 237: anti pd antibody ctla programmed death cell targeting lymphocyte cytotoxic
Cluster 238: hbac glycosylated hemoglobin ac hb measurement equal registration days prior
Cluster 239: seizure disorder uncontrolled history patients seizures active generalized months medication
Cluster 240: specific study provide informed consent entry patient prior representative legally
Cluster 241: grade alopecia toxicities recovered prior related adverse toxicity therapy patients
Cluster 242: myelosuppressive weeks nitrosourea anticancer received chemotherapy study prior dose known
Cluster 243: cells platelets mm days prior registration obtained entry study experiencing
Cluster 244: qt interval qtc corrected msec qtcf fridericia formula electrocardiogram ms
Cluster 245: mmol dl normalize mg despite intervention levels calcium hemoglobin adjusted
Cluster 246: overlap fields region result radiotherapy radiation cancer therapy prior study
Cluster 247: ain anal stain intraepithelial neoplasia hsil proven biopsy cyclin junction
Cluster 248: bowel gastrointestinal vomiting absorption nausea resection disease significantly inflammatory diseases
Cluster 249: prohibited use bisphosphonates herbal concurrent dhea ephedra ginseng dehydroepiandrosterone yohimbe
Cluster 250: olaparib chemical composition compounds attributed reactions similar allergic biologic cediranib
Cluster 251: hgb hemoglobin dl obtained transfusions registration days prior allowed procurement
Cluster 252: live vaccine attenuated influenza vaccines vaccination flu seasonal dose study
Cluster 253: consecutive undergone childbearing potential months orientation naturally meets sexual ligation
Cluster 254: upper limit normal creatinine uln institutional ast serum prothrombin alt
Cluster 255: registration therapy days prior radiation treatment investigational immunotherapy chemotherapy mitomycin
Cluster 256: hiv cd immunodeficiency cluster differentiation positive virus human antiretroviral count
Cluster 257: fast mln maintain oral hour hours medication administration required bowel
Cluster 258: neuropathy grade peripheral greater patients severity exceeds registration sensory permitted
Cluster 259: intact capsules swallow able patients subprotocol subprotocols assigned general tablets
Cluster 260: cooperative eastern ecog group oncology performance status ps patients score
Cluster 261: fcbp pregnancy lenalidomide agree effective method childbearing consecutive days commit
Cluster 262: allografts organ patients zubrod experimental expert expiratory explained exploratory exposed
Cluster 263: chemotherapy prior neoadjuvant patients received therapy treatment surgery radiation adjuvant
Cluster 264: lar representative legally authorized understand document willingness ability sign written
Cluster 265: sun exposure sunscreen protection excessive anticipated avoid willingness adequate use
Cluster 266: evaluable measurable disease patients parts radiologically recist ca participants clinically
Cluster 267: olaparib mother breastfeeding discontinued cediranib treated pregnant excluded women study
Cluster 268: ppi pump proton inhibitor receiving dose study concomitant stop using
Cluster 269: gilbert bilirubin total uln syndrome upper limit normal exception institutional
Cluster 270: lactating breastfeed females plan infants eligible excluded exposure expert expiratory
Cluster 271: wocbp women contraception nivolumab potential men postmenopausal childbearing use instructed
Cluster 272: bilirubin total upper institutional normal limit direct range sequencing allowed
Cluster 273: surgery major weeks recovered prior effects patients placement surgical study
Cluster 274: women childbearing potential contraception adequate employ unwilling practice male men
Cluster 275: cancers skin patient thyroid advanced known active basal screening squamous
Cluster 276: breastfeed lactating agreed infants unless females eligible female pregnancy potential
Cluster 277: cbc differential obtained blood count registration days complete step prior
Cluster 278: currently agents anti receiving cancer eligible patients anticancer platelet study
Cluster 279: receiving agents eligible corticosteroid currently anti corticosteroids investigational cypa drugs
Cluster 280: permits psychological general follow health ability completion requirements required study
Cluster 281: bilirubin mg dl total direct serum gilbert patient syndrome registration
Cluster 282: cypc strong inducers inhibitors cyp cytochrome week preceding cypa alternative
Cluster 283: malignancy melanotic cancer specific cervix situ skin carcinoma exceptions prior
Cluster 284: cavitating radiographic pulmonary lesion evidence subject participant extended extensive extent
Cluster 285: approaching biospecimens department regarding check release investigators submission pathology site
Cluster 286: identity process ensure board approval order open entered date institution
Cluster 287: bun urea nitrogen blood mg dl chloride bicarbonate glucose phosphatase
Cluster 288: measurable neuroblastoma lesions disease detected fluid mibg bone collections gallium
Cluster 289: tablets swallow able unable intact patients subject ability eligible chewed
Cluster 290: tissue tumor biopsy available archival submission slides paraffin patients block
Cluster 291: immunotherapies activating conjugates brentuximab prior vedotin restrictions checkpoint purposes monoclonal
Cluster 292: creatinine gault cockcroft clearance min ml equation using calculated formula
Cluster 293: cycle day herbal therapy week weeks prior contraceptives anticancer radiotherapy
Cluster 294: inhibitors azacitidine decitabine deacetylase histone hydroxyurea interferon tyrosine hematopoietic thalidomide
Cluster 295: autoimmune disease systemic syndrome replacement history patients sclerosis treatment arthritis
Cluster 296: cycle day investigational agent weeks treatment prior past agents received
Cluster 297: dipg stratum progressed progressive recurrent non patients irradiation refractory enrollment
Cluster 298: dimension mm ct diameter lesion spiral longest recorded measurable accurately
Cluster 299: infection active requiring systemic antibiotics severe patients therapy fungal septicemia
